🔎 Trials Near Me

Dachaigh › Aillse a' bhroilleach › Pennsylvania

Sgrùdaidhean clionaigeach Aillse a' bhroilleach ann an Pennsylvania

Tha 93 sgrùdaidhean airson Aillse a' bhroilleach a’ lorg phàirtichean aig làraichean ann an Pennsylvania.

Bailtean ann an Pennsylvania

Teacsa sgrùdaidh oifigeil (Beurla)

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

  • Lehigh Valley Health Network (Data Collection Only), Allentown
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05534438

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
  • University of Pittsburgh Medical Center, Pittsburgh
  • WellSpan York Cancer Center, York
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT04585750

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

  • Consultants In Med Onco And Hema, Drexel Hill
  • Univ of Pittsburg Med Ctr Pinnacle, Harrisburg
  • Allegheny Health Network, Pittsburgh
A’ fastadhÌre 3
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05827081

Distance-Based Exercise to Preserve Function and Prevent Disability

  • UPMC Hillman Cancer Center at Butler Health System, Butler
  • IRMC Cancer Center, Indiana
  • UPMC Hillman Cancer Center - New Castle, New Castle
  • agus 2 a bharrachd
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07059884

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • agus 7 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Alliance Cancer Specialists, Horsham
  • University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
  • University of Pittsburgh (UPMC), Pittsburgh
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06369285

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

  • Allegheny General Hospital, Pittsburgh
A’ fastadhSgrùdadh amharc
Aoisean 20 gu 89 · Banairean · Air ùrachadh 30 Sult 2026 · NCT07023887

A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
  • Allegheny General Hospital, Pittsburgh
A’ fastadh
Aoisean 20 gu 89 · Banairean · Air ùrachadh 30 Sult 2026 · NCT07698314

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • Penn State Milton S. Hershey Medical Center, Hershey
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT06324357

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Pittsburgh
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT05877599

EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
  • AHN Allegheny General Hospital, Pittsburgh
A’ fastadh
Aoisean 20 gu 89 · Banairean · Air ùrachadh 28 Sult 2026 · NCT07704476

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Philadelphia
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05867251

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058), Pittsburgh
  • Cancer Care Associates Of York ( Site 0063), York
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07060807

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  • Penn Medicine - Lancaster General Hospital, Lancaster
  • Capital Health Hematology Oncology Specialists, Newton
  • Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
  • agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 60 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06377852

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

  • University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
A’ fastadh
Aoisean 30 agus nas sine · Banairean · Air ùrachadh 25 Sult 2026 · NCT02945579

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Allegheny (AHN), Pittsburgh
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07214532

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Horsham
  • Clinical Trial Site, Sayre
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07085767

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • University of Pittsburgh Medical Center, Pittsburgh
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • University of Pennsylvania, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07213791

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • St. Luke's University Health Network, Bethlehem
  • Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
  • University of Pennsylvania Hospital, Philadelphia
  • agus 3 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07174336

Identifying Patterns in the Breath of Individuals With Breast Cancer

  • Weinstein Imaging Associates, Pittsburgh
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 74 · Banairean · Air ùrachadh 18 Sult 2026 · NCT06512350

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT07340541

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Lehigh Valley Health Network - Cedar Crest, Allen
  • Consultants In Medical Oncology and Hematology, P.C., Broomall
  • Penn State Milton S. Hershey Medical Center, Hershey
  • agus 5 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT06492616

Active Surveillance in Older Women With ER+ Breast Cancer

  • University of Pittsburgh Medical Center, Pittsburgh
A’ fastadhSgrùdadh amharc
Aoisean 70 agus nas sine · Banairean · Air ùrachadh 11 Sult 2026 · NCT07262138

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  • Research Site, Pittsburgh
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT05123482

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

  • St. Luke's University Health Network, Bethlehem
  • Guthrie Medical Group, Sayre
A’ fastadhÌre 1
Aoisean 18 gu 55 · Banairean · Air ùrachadh 9 Sult 2026 · NCT07310420

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

  • Penn State Health Milton S. Hershey Medical Center, Hershey
  • University of Pennsylvania - Abramson Cancer Center, Philadelphia
  • UPMC - Hillman Cancer Center, Pittsburgh
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

  • University of Pennsylvania, Philadelphia
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT05315700

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

  • Penn State Cancer Institute, Hershey
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT04886531

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT07216105

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

  • Abramson Cancer Center, Philadelphia
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT05964504

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Bryn Mawr Hospital, Bryn Mawr
  • agus 56 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 60 · Banairean · Air ùrachadh 2 Sult 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • UPMC Hillman Cancer Center, Pittsburgh
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT07029399

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
  • UPMC, Pittsburgh
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Lùna 2026 · NCT06774963

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT02732171

ATEMPT 2.0: Adjuvant T-DM1 vs TH

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia
  • University of Pittsburgh Medical Center Cancer UPMC- Magee Women's Hospital, Pittsburgh
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Lùna 2026 · NCT04893109

Biennial CEM in Women With a Personal History of Breast Cancer

  • UPMC Magee-Womens Imaging - Bethel Park, Bethel Park
  • UPMC Magee at the Lemieux Sports Complex, Cranberry Township
  • Magee Womancare Monroeville, Monroeville
  • agus 3 a bharrachd
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 30 gu 79 · Banairean · Air ùrachadh 19 Lùna 2026 · NCT06105749

EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer

  • AHN Allegheny General Hospital, Pittsburgh
A’ fastadh
Aoisean 20 gu 89 · Banairean · Air ùrachadh 17 Lùna 2026 · NCT07739563

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.